The radiosensitivity index predicts for overall survival in glioblastoma

We have previously developed a multigene expression model of tumor radiosensitivity (RSI) with clinical validation in multiple cohorts and disease sites. We hypothesized RSI would identify glioblastoma patients who would respond to radiation and predict treatment outcomes. Clinical and array based gene expression (Affymetrix HT Human Genome U133 Array Plate Set) level 2 data was downloaded from the cancer genome atlas (TCGA). A total of 270 patients were identified for the analysis: 214 who underwent radiotherapy and temozolomide and 56 who did not undergo radiotherapy. Median follow-up for the entire cohort was 9.1 months (range: 0.04–92.2 months). Patients who did not receive radiotherapy were more likely to be older (p < 0.001) and of poorer performance status (p < 0.001). On multivariate analysis, RSI is an independent predictor of OS (HR = 1.64, 95% CI 1.08–2.5; p = 0.02). Furthermore, on subset analysis, radiosensitive patients had significantly improved OS in the patients with high MGMT expression (unmethylated MGMT), 1 year OS 84.1% vs. 53.7% (p = 0.005). This observation held on MVA (HR = 1.94, 95% CI 1.19–3.31; p = 0.008), suggesting that RT has a larger therapeutic impact in these patients. In conclusion, RSI predicts for OS in glioblastoma. These data further confirm the value of RSI as a disease-site independent biomarker.

[1]  S. Eschrich,et al.  Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. , 2014, International journal of radiation oncology, biology, physics.

[2]  Steven Eschrich,et al.  Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. , 2009, International journal of radiation oncology, biology, physics.

[3]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[4]  L. Gaspar,et al.  Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. , 2011, International journal of radiation oncology, biology, physics.

[5]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.

[6]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[7]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[8]  David Boulware,et al.  A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. , 2009, International journal of radiation oncology, biology, physics.

[9]  P. Brown,et al.  Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme , 2012, Cancer.

[10]  Ping Li,et al.  A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway , 2014, Oncotarget.

[11]  E. B. Butler,et al.  Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[12]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[13]  Walter J Curran,et al.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[15]  S. Eschrich,et al.  A Molecular Signature of Radiosensitivity (RSI) is an RT-specific Biomarker in Prostate Cancer , 2014 .

[16]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[17]  Benedick A Fraass,et al.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[19]  K. Sultanem,et al.  The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. , 2004, International journal of radiation oncology, biology, physics.

[20]  James A. Purdy,et al.  Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. , 2009, International journal of radiation oncology, biology, physics.

[21]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[22]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[23]  Yuichiro Narita,et al.  Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. , 2006, International journal of radiation oncology, biology, physics.

[24]  Yudi Pawitan,et al.  Validation of a Radiosensitivity Molecular Signature in Breast Cancer , 2012, Clinical Cancer Research.

[25]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Shigemori,et al.  A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme , 2011, Journal of Neuro-Oncology.

[27]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[28]  Simone Kreth,et al.  O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation , 2011, PloS one.

[29]  M. J. van de Vijver,et al.  Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. , 2015, International journal of radiation oncology, biology, physics.

[30]  Steven Eschrich,et al.  Prediction of radiation sensitivity using a gene expression classifier. , 2005, Cancer research.

[31]  G. Shenouda,et al.  Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. , 2007, International journal of radiation oncology, biology, physics.

[32]  Hak Choy,et al.  International Journal of Radiation Oncology Biology Physics: Introduction , 2004 .

[33]  T. Strom,et al.  Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.